PLX - Protalix BioTherapeutics, Inc.
2.12
-0.030 -1.415%
Share volume: 722,028
Last Updated: 05-01-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances:
0.23%
PREVIOUS CLOSE
CHG
CHG%
$2.15
-0.03
-0.01%
View ratios
| Fiscal Date | 09-30-2024 | 12-31-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 11-14-2024 | 03-17-2025 | 05-09-2025 | 08-14-2025 | 11-13-2025 | 03-18-2026 | |
| Total revenue | 17.959 M | 18.218 M | 10.113 M | 15.658 M | 17.851 M | 9.122 M | |
| Cost of revenue | 8.375 M | 3.886 M | 8.180 M | 5.870 M | 8.324 M | 4.619 M | |
| Gross profit | 9.584 M | 14.332 M | 1.933 M | 9.788 M | 9.527 M | 4.503 M | |
| 49.54% | -86.51% | 406.36% | -2.67% | -52.73% | |||
| Operating expenses | 5.593 M | 7.123 M | 6.078 M | 8.616 M | 7.396 M | 9.161 M | |
| Selling general and admin | 2.595 M | 2.999 M | 2.603 M | 2.624 M | 2.929 M | 3.526 M | |
| Research and development | 2.998 M | 4.124 M | 3.475 M | 5.992 M | 4.467 M | 5.635 M | |
| Total expenses | 5.593 M | 7.123 M | 6.078 M | 8.616 M | 7.396 M | 9.161 M | |
| 27.36% | -14.67% | 41.76% | -14.16% | 23.86% | |||
| Operating income | 3.991 M | 7.209 M | -4.145 M | 1.172 M | 2.131 M | -4.658 M | |
| Ebit | 3.843 M | 7.316 M | -3.732 M | 661.000 K | 2.239 M | -4.776 M | |
| Pretax income | 3.843 M | 7.316 M | -3.732 M | 661.000 K | 2.239 M | -4.776 M | |
| 90.37% | -151.01% | -117.71% | 238.73% | -313.31% | |||
| Income tax | 607.000 K | 822.000 K | -113.000 K | 497.000 K | -116.000 K | 728.000 K | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | 3.236 M | 6.494 M | -3.619 M | 164.000 K | 2.355 M | -5.504 M | |
| 100.68% | -155.73% | 104.53% | 1,335.98% | -333.72% |